Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials -

Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials
Information type: Other primary research
Source: Journal of Clinical Oncology
Specialities:
Summary
Analysis (MILES-3, n=299; MILES-4, n=232) found that addition of cisplatin to single-agent chemotherapy (gemcitabine or pemetrexed) does not significantly prolong overall survival (HR, 0.86; 95% CI, 0.70 to 1.05; P = 0.14) nor improve quality of life in this setting.
UKMi comment
A related editorial discusses the question of when to offer new treatments to older patients who are considered a heterogeneous population with respect to comorbidities and functionality and with respect to life expectancy.
Related links: Editorial